[Hengrui Medicine: Subsidiary SHR-8925 for injection has been approved for clinical trials] On November 13, Hengrui Medicine (600276.SH) announced that the company's subsidiary Suzhou Shengdia Biomedicine Co., Ltd. has received the "Drug Clinical Trial Approval Notice" for SHR-8925 for injection approved and issued by the State Food and Drug Administration, agreeing to conduct clinical trials of this drug as a single agent in patients with advanced solid tumors. The drug is a therapeutic biological product independently developed by the company. It is intended to be used to treat advanced solid tumors. No drug with the same target has been approved for marketing at home and abroad. The cumulative investment in R&D of related projects is approximately 11.2 million yuan.